What happened
EMA announced its first bilateral meeting with the Active Pharmaceutical Ingredients Committee (APIC), organised within EMA’s annual bilateral meetings with industry stakeholder organisations. The meeting is scheduled for 2 September 2026 from 15:30 to 17:30 CEST at EMA in Amsterdam, the Netherlands. Its stated purpose is to exchange views and promote dialogue on topics of common interest. Participation is by invitation only. The page lists an agenda, first published on 31 July 2026 and updated on 23 September 2026, and a highlights report, reference EMA/199326/2026, first published on 23 September 2026.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, the meeting may matter because it provides dialogue between EMA and an active pharmaceutical ingredients industry committee. Manufacturers may wish to monitor the published agenda and highlights for subjects discussed between EMA and APIC. However, the supplied page does not describe the agenda topics, report findings, regulatory expectations, or resulting changes. No specific GMP requirement or manufacturing action can therefore be inferred from this source alone.
Key topics: First EMA-APIC bilateral meeting, Dialogue on active pharmaceutical ingredient topics, Published meeting agenda and highlights
Source: European Medicines Agency (EMA)